MedTrace Logo

Sunitinib Non Small Cell Lung Cancer Patients Over 70

NCT00864721 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2018-10-16

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to find out what effects (good and bad) sunitinib has on patients and their NSCLC.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Sutent

Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • US Oncology Research

    lead INDUSTRY

Principal Investigators

  • Craig H. Reynolds, MD · US Oncology Research, LLC; Ocala Oncology Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2012-07-31
Completion
2012-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00864721 on ClinicalTrials.gov